[1] CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J :Engl,2021,134(7):783-791.
[2] 陈琼. 2003～2007年中国结直肠癌发病与死亡分析[J]. 中国肿瘤, 2012, 21(3):179-182.
[3] 葛素梅, 强贤, 程羽青,等. 肿瘤相关巨噬细胞亚型在子宫内膜癌中的表达和意义[J]. 南京医科大学学报(自然科学版), 2022, 42(2): 189-193,215.
[4] MIAO X, LIU Y, FAN Y, et al. LncRNA BANCR attenuates the killing capacity of cisplatin on gastric cancer cell through the ERK1/2 pathway[J]. Cancer Manag Res,2021,13:287-296.
[5] PENG M, WEI G, ZHANG Y, et al. Single-cell transcriptomic landscape reveals the differences in cell differentiation and immune microenvironment of papillary thyroid carcinoma between genders[J]. Cell Biosci,2021,11(1):39.
[6] VITALE I, MANIC G, COUSSENS L M, et al. Macrophages and metabolism in the tumor microenvironment[J]. Cell Metab,2019,30(1):36-50.
[7] 何岸江,胡卫军,李霄,等. CD68+、CD163+巨噬细胞在结直肠癌组织中的浸润及意义[J]. 结直肠肛门外科,2017,23(4):440-444.
[8] SOLINAS G, GERMANO G, MANTOVANI A, et al. Tumor-associated macrophages(TAM) as major players of the cancer-related inflammation[J]. J Leukoc Biol, 2009, 86(5):1065-1073.
[9] LANDSMAN L, BAR-ON L, ZERNECKE A, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival[J]. Blood, 2009, 113(4):963-972.
[10] MITCHELL D A, BATICH K A, GUNN M D, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients[J]. Nature,2015,519(7543):366-369.
[11] YANG X, LU P, FUJII C, et al. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression[J]. Int J Cancer,2006,118(8):1869-1876.
[12] LIAO Y Y, TSAI H C, CHOU P Y, et al. CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells[J]. Oncotarget,2016,7(4):4310-4325.
[13] HSU C J, WU M H, CHEN C Y, et al. AMP-activated protein kinase activation mediates CCL3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma[J]. Cell Commun Signal,2013,11:68.
[14] SILVA T A, RIBEIRO F L, OLIVEIRA-NETO H H, et al. Dual role of CCL3/CCR1 in oral squamous cell carcinoma:implications in tumor metastasis and local host defense[J].Oncol Rep,2007,18(5):1107-1113.
[15] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E386.
[16] ARGYLE D, KITAMURA T. Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors[J]. Front Immunol, 2018, 9:2629.
[17] BURGER J A, QUIROGA M P, HARTMANN E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation[J]. Blood, 2009, 113(13):3050-3058.
[18] BROXMEYER H E, COOPER S, HANGOC G, et al. Dominant myelopoietic effector functions mediated by chemokine receptor CCR1[J]. J Exp Med,1999,189(12):1987-1992.
[19] CHANMEE T, ONTONG P, KONNO K, et al. Tumor-associated macrophages as major players in the tumor microenvironment[J]. Cancers:Basel,2014,6(3):1670-1690.
[20] ZUCCHETTO A, BENEDETTI D, TRIPODO C, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival[J]. Cancer Res, 2009, 69(9):4001-4009. |
